NOXXON Reports H1 2021 Financial Results and Provides Business Update
Positive results from two cohorts of Phase 1/2 clinical trial with NOX-A12 in brain cancer; full readout expected in Q1 2022 Appointment of Scientific Advisory Board with top US and EU pancreatic cancer experts Appointment of 3 new Supervisory Board members with remarkable experience Strengthening the Company’s balance sheet by raising a total of €9.3 […]










